Active Smallcap & Microcap Investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$CATV is on the verge of a game-changing acquisition! Their pending merger with Genetic Networks will put them on the map by integrating the proprietary GeneScape tech already used by top biopharma companies into their portfolio. Get caught up here:
$CATV is on the verge of a game-changing acquisition! Their pending merger with Genetic Networks will put them on the map by integrating the proprietary GeneScape tech already used by top biopharma companies into their portfolio.
— Degen Magazine (@DegenMagazine) July 8, 2024
Get caught up here:https://t.co/mYplaFoOFv
$CATV News: Category V Biotech, Inc. Announces Exclusive Licensing of Genetic Networks' Intellectual Property for Cannabis Applications
FLORIDA, July 2, 2024 – Category V Biotech, Inc. (OTC: CATV), formerly known as 4Cable TV International, Inc., is pleased to announce significant progress in our relationship with Genetic Networks, LLC (https://geneticnetworks.com/).
While continuing to analyze the acquisition, Category V Biotech and Genetic Networks have agreed to allow CATV to become the exclusive licensee of all Genetic Networks’ intellectual property and technology worldwide for cannabis applications. This agreement allows Genetic Networks time to address internal matters found during due diligence, while Category V Biotech begins its journey into the discovery of medicines using cannabis. This licensing agreement will facilitate close collaboration with Genetic Networks on cannabis research and development, positioning Category V Biotech as a leader in developing cannabis medicines.
Our goal is to screen cannabis and cannabis-derived products to determine their medicinal benefits by utilizing Genetic Networks' extensive disease database accumulated over the past decade while working for pharmaceutical companies and government. Discovering the use of cannabis for specific diseases is key to developing medicines that can be registered with regulatory bodies worldwide and distributed for medical use or treatment.
The exclusive licensing of Genetic Networks’ technologies, including their proprietary platform GeneScape™, will facilitate the rapid and unbiased discovery of optimal drug compounds from cannabis through whole-genome analysis. This exclusive license allows Category V Biotech to expand into the biotech sector of the cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.
"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before, as regulated FDA products under the new regulatory environment of the United States." Dr. Gennaro D’Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."
Upon resolving internal matters identified during due diligence, Category V Biotech will complete the acquisition of Genetic Networks. Following the transaction, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global cannabis operations, including cultivation, biotech research, and retail. This transaction culminates years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using cannabis.
The recent changes in the rescheduling of cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, has paved the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the cannabis industry, driving innovation and advancing therapeutic solutions for patients. Category V Biotech remains actively engaged in pursuing additional acquisitions in the cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.
About Genetic Networks, LLC
Established in 2015, Genetic Networks, LLC has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis. About Category V Biotech, Inc. Category V Biotech, Inc. (OTC: CATV) aims to establish and operate a fully integrated global cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical cannabis-based products and therapies.
$CATV is on the verge of a game-changing acquisition! Their pending merger with Genetic Networks will put them on the map by integrating the proprietary GeneScape tech already used by top biopharma companies into their portfolio. Get caught up here:
$CATV is on the verge of a game-changing acquisition! Their pending merger with Genetic Networks will put them on the map by integrating the proprietary GeneScape tech already used by top biopharma companies into their portfolio.
— Degen Magazine (@DegenMagazine) July 8, 2024
Get caught up here:https://t.co/mYplaFoOFv
Safety Shot Terminates Partnership With Brand Ambassador Ryan Garcia Following Disparaging Remarks
Safety Shot Has Zero-Tolerance For Any Sort Of Hate Speech
JUPITER, Fla., July 8, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) announces the termination of its partnership with professional boxer Ryan Garcia.
Safety Shot has a zero-tolerance policy towards discrimination and upholds the highest standards for its brand ambassadors. Safety Shot has effectively severed ties and terminated the relationship whereby Ryan Garcia no longer has any association with nor is a brand ambassador of Safety Shot.
"We do not tolerate any form of disrespect to members of our community," said Safety Shot CEO, Jarrett Boon. "It is of the utmost importance that the people representing Safety Shot align with our core values. While we are severely disappointed in Mr. Garcia's failure to live up to our Company's standards, we wish him luck as he enters drug and alcohol rehab and attempts to turn his life around."
For more information, visit http://www.drinksafetyshot.com.
About Safety Shot, Inc
Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.
https://c212.net/c/img/favicon.png?sn=LA55684&sd=2024-07-08 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-terminates-partnership-with-brand-ambassador-ryan-garcia-following-disparaging-remarks-302190477.html
$CYCA: Cytta Corp and FIZUAS Team Up to Enhance Drone and Streaming Tech for Law Enforcement: Cytta Corp. (Stock Symbol: CYCA)
June 25, 2024
Click here:
https://www.einpresswire.com/article/722643501/cytta-corp-and-fizuas-team-up-to-enhance-drone-and-streaming-tech-for-law-enforcement-cytta-corp-stock-symbol-cyca
From the article:
Technology Solutions Provider Addressing Various Industries for Integration, Streaming, Transfer and Storage of Video and Audio Data.
Partnered with FIZUAS Unmanned Aircraft Systems to Dominate the American Drone Reseller and Advanced Streaming Technology Market.
Launched Crisis Alert and Response Emergency System Mobile Application to Revolutionize School Safety.
Instant SOS Alert Automatically Triggers a Video Call That is Shared with All Emergency Responders Responsible for Protecting a School.
Initiative for Florida Law Enforcement Agencies Generates Overwhelming Response Amid New Drone Regulation Changes.
Strong Success for Groundbreaking AI-Enhanced Marketing Campaign in Florida.
Multiple Florida Police Departments and Sheriff's Offices Choosing CYCA CyttaCOMMS as their Drone Streaming Solution.
$CYCA: Cytta Corp and FIZUAS Team Up to Enhance Drone and Streaming Tech for Law Enforcement: Cytta Corp. (Stock Symbol: CYCA)
June 25, 2024
Click here:
https://www.einpresswire.com/article/722643501/cytta-corp-and-fizuas-team-up-to-enhance-drone-and-streaming-tech-for-law-enforcement-cytta-corp-stock-symbol-cyca
From the article:
Technology Solutions Provider Addressing Various Industries for Integration, Streaming, Transfer and Storage of Video and Audio Data.
Partnered with FIZUAS Unmanned Aircraft Systems to Dominate the American Drone Reseller and Advanced Streaming Technology Market.
Launched Crisis Alert and Response Emergency System Mobile Application to Revolutionize School Safety.
Instant SOS Alert Automatically Triggers a Video Call That is Shared with All Emergency Responders Responsible for Protecting a School.
Initiative for Florida Law Enforcement Agencies Generates Overwhelming Response Amid New Drone Regulation Changes.
Strong Success for Groundbreaking AI-Enhanced Marketing Campaign in Florida.
Multiple Florida Police Departments and Sheriff's Offices Choosing CYCA CyttaCOMMS as their Drone Streaming Solution.
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
Yes, this new interview with AVRW CEO Nancy Duitch clearly illustrates her strengths and experience in developing an emerging business. With Nancy's leadership and the proven value in the Avenir Wellness product line, AVRW should have prosperous future ahead.
------------------------------------------------------------------------------------------------------------
Nancy Duitch serves as the CEO of Avenir Wellness Solutions. With over three decades of experience in the consumer products sector, Nancy has cultivated a diverse array of businesses, guiding them from inception to the public market. Her expertise extends to orchestrating cutting-edge marketing and branding initiatives, resulting in a staggering $3 billion in revenue for esteemed brands. From her early years, Nancy exhibited a clear vision and pursued it with determination.
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$BIVI & $BIAF: BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
BioVie: https://www.redchip.com/assets/access/bivi_access
bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_access
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFa production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. bioAffinity Technologies is an emerging player in early-stage cancer diagnosis. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD's purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Company's flow cytometry platform, enhanced by AI-driven automated data analysis, is being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach $8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the Company with ownership at 39% and increasing. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NF?B (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit http://www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
BioVie: https://www.redchip.com/assets/access/bivi_access
bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_access
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFa production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. bioAffinity Technologies is an emerging player in early-stage cancer diagnosis. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD's purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Company's flow cytometry platform, enhanced by AI-driven automated data analysis, is being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach $8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the Company with ownership at 39% and increasing. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NF?B (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit http://www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$IVDN is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$AVRW: Interview with Nancy Duitch, CEO Avenir Wellness Solutions (OTC: AVRW)
May 3, 2024
Nancy Duitch serves as the CEO of Avenir Wellness Solutions. With over three decades of experience in the consumer products sector, Nancy has cultivated a diverse array of businesses, guiding them from inception to the public market. Her expertise extends to orchestrating cutting-edge marketing and branding initiatives, resulting in a staggering $3 billion in revenue for esteemed brands. From her early years, Nancy exhibited a clear vision and pursued it with determination. Her knack for crafting iconic brands for infomercials and direct-to-consumer channels has solidified her position as one of the most sought-after female CEOs in the industry. Join us as we delve into Nancy's journey, experiencing her infectious energy and enthusiasm as a lifelong entrepreneur who truly lives life to the fullest.
Interview with Nancy Duitch, CEO, Avenir Wellness Solutions, Inc. (OTC: AVRW)
May 3, 2024
Nancy Duitch serves as the CEO of Avenir Wellness Solutions. With over three decades of experience in the consumer products sector, Nancy has cultivated a diverse array of businesses, guiding them from inception to the public market. Her expertise extends to orchestrating cutting-edge marketing and branding initiatives, resulting in a staggering $3 billion in revenue for esteemed brands. From her early years, Nancy exhibited a clear vision and pursued it with determination. Her knack for crafting iconic brands for infomercials and direct-to-consumer channels has solidified her position as one of the most sought-after female CEOs in the industry. Join us as we delve into Nancy's journey, experiencing her infectious energy and enthusiasm as a lifelong entrepreneur who truly lives life to the fullest.
$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market
Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership
LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.
A Strategic Move in Response to Growing Demand
This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.
Quote from Mike Elliott, VP of Business Development
"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."
Expanding CyttaAIR's Reach
This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.
About Cytta Corp:
Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.
The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
About FIZUAS Unmanned Aircraft Systems
FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.
Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662
Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708
SOURCE: Cytta Corp.
https://finance.yahoo.com/news/cyttaair-partners-fizuas-dominate-american-120000070.html
$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market
Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership
LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.
A Strategic Move in Response to Growing Demand
This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.
Quote from Mike Elliott, VP of Business Development
"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."
Expanding CyttaAIR's Reach
This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.
About Cytta Corp:
Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.
The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
About FIZUAS Unmanned Aircraft Systems
FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.
Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662
Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708
SOURCE: Cytta Corp.
https://finance.yahoo.com/news/cyttaair-partners-fizuas-dominate-american-120000070.html
$CATV News: Category V Biotech, Inc. Announces Exclusive Licensing of Genetic Networks' Intellectual Property for Cannabis Applications
FLORIDA, July 2, 2024 – Category V Biotech, Inc. (OTC: CATV), formerly known as 4Cable TV International, Inc., is pleased to announce significant progress in our relationship with Genetic Networks, LLC (https://geneticnetworks.com/).
https://www.otcmarkets.com/stock/CATV/news/CATV-signs-Exclusive-Licensing-Deal-with-Genetic-Networks-for-Cannabis-Research?id=445565
$CATV News: Category V Biotech, Inc. Announces Exclusive Licensing of Genetic Networks' Intellectual Property for Cannabis Applications
FLORIDA, July 2, 2024 – Category V Biotech, Inc. (OTC: CATV), formerly known as 4Cable TV International, Inc., is pleased to announce significant progress in our relationship with Genetic Networks, LLC (https://geneticnetworks.com/).
https://www.otcmarkets.com/stock/CATV/news/CATV-signs-Exclusive-Licensing-Deal-with-Genetic-Networks-for-Cannabis-Research?id=445565
$AVRW Seratopical skin care products are keeping the famous Nicole Kidman looking her best. Everyone can clearly see this.
When it comes to anti-aging skincare, Kidman's loyalty lies with Seralabs. Kidman, who has been working with the brand since 2020, told InStyle that she “loves using Seratopical because it makes my skin smooth and hydrated.” In honor of the brand ambassador’s birthday, Seralabs is offering 30 percent off sitewide all week with the code NK30.
LINK:
https://www.instyle.com/nicole-kidman-birthday-favorite-beauty-products-8666305?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons
$AVRW Seratopical skin care products are keeping the famous Nicole Kidman looking her best. Everyone can clearly see this.
When it comes to anti-aging skincare, Kidman's loyalty lies with Seralabs. Kidman, who has been working with the brand since 2020, told InStyle that she “loves using Seratopical because it makes my skin smooth and hydrated.” In honor of the brand ambassador’s birthday, Seralabs is offering 30 percent off sitewide all week with the code NK30.
LINK:
https://www.instyle.com/nicole-kidman-birthday-favorite-beauty-products-8666305?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons
$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market
Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership
LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.
A Strategic Move in Response to Growing Demand
This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.
Quote from Mike Elliott, VP of Business Development
"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."
Expanding CyttaAIR's Reach
This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.
About Cytta Corp:
Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.
The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
About FIZUAS Unmanned Aircraft Systems
FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.
Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662
Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708
SOURCE: Cytta Corp.
https://finance.yahoo.com/news/cyttaair-partners-fizuas-dominate-american-120000070.html
$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market
Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership
LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.
A Strategic Move in Response to Growing Demand
This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.
Quote from Mike Elliott, VP of Business Development
"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."
Expanding CyttaAIR's Reach
This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.
About Cytta Corp:
Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.
The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
About FIZUAS Unmanned Aircraft Systems
FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.
Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662
Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708
SOURCE: Cytta Corp.
https://finance.yahoo.com/news/cyttaair-partners-fizuas-dominate-american-120000070.html
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
Nice close at the high of the week for AVRW. More investors are realizing that this stock has plenty of upside reward potential from its current oversold levels and they are accumulating for the long term.
Avenir Wellness Solutions, Inc. AVRW: OTC Markets
At close: 4:00:00 PM ET, 06/28/2024
Last $0.0519 +$0.0019 (+3.80%)
Day High .0519
Day Low .0459
Volume: 13,000
Previous close $0.0500
Today's open $0.0459
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$AVRW: How Seratopical Revolution by Nicole Kidman Is Changing The Game
Learn how Nicole Kidman and Nancy Duitch, founder and CEO of SeraLabs and Chief Strategic Officer of CURE Pharmaceutical have joined forces to launch SeraLabs' Seratopical Revolution, a plant-based, alcohol-free, anti-aging beauty line.
$AVRW: How Seratopical Revolution by Nicole Kidman Is Changing The Game
Learn how Nicole Kidman and Nancy Duitch, founder and CEO of SeraLabs and Chief Strategic Officer of CURE Pharmaceutical have joined forces to launch SeraLabs' Seratopical Revolution, a plant-based, alcohol-free, anti-aging beauty line.
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing
New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 2024, based on two positive trials 1 2 and Breakthrough Therapy Designation. Potential revenue in 2025
NDA for NRX-100 (IV ketamine) in suicidal depression in advanced preparation for submission in 2024; based on four positive trials 3 4 5 6 and Fast Track Designation. Potential revenue in 2025
Gaining these approvals has the potential to yield more than $150 in revenue per NRXP share in the near term, at current share count
Planning for HOPE Therapeutics share distribution progresses; audit nearing completion – critical step towards a public listing
RADNOR, Pa., June 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that advice from regulatory counsel, which includes former senior officials from the Food and Drug Administration, supports filing two New Drug Applications (NDAs) in 2024: an application for Accelerated Approval for NRX-101 to treat bipolar depression in patients with akathisia and an application for approval of NRX-100 (IV ketamine) for treatment of suicidal depression.
(PRNewsfoto/NRx Pharmaceuticals)
(PRNewsfoto/NRx Pharmaceuticals)
While efficacy and safety data are now in hand, filing of the above applications is dependent upon completion of 12-month stability data in manufactured lots as required by FDA regulations.
As disclosed in an 8K filing, NRx will be filing the NRX-101 application without a commercial partner. The addressable market for the accelerated approval indication is such that a compact and efficient salesforce can be constructed by a small company, such as NRx, and current executives at NRx have previously held primary responsibility for launch of similar-sized pharmaceutical assets.
NRx continues work to enable the distribution of shares in Hope Therapeutics. This distribution is dependent upon completion of a public audit and successful review of an SEC Form 10.
"The NRx team has worked diligently since the end of the COVID pandemic to achieve these milestones for our shareholders and most importantly the patients we have always sought to help," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "Given the near-term market opportunity represented by an accelerated approval process, NRx anticipates a higher potential return to NRx investors associated with an NRx-led initiative than that which would likely be achieved with a large commercial partner."
NRX-101 for Bipolar Depression
NRX-101 is the Company's patented (Composition of Matter), oral combination of the NMDA antagonist D-cycloserine and lurasidone for bipolar depression. Data from two active control clinical trials vs. the standard of care, lurasidone, have shown comparable antidepressant efficacy with clinically important reductions in suicidality and/or akathisia. To the Company's knowledge, no other oral agent has demonstrated such a valuable profile.
Up to 15% of people treated with drugs in lurasidone's class develop akathisia7; this would constitute an estimated $3.7 billion initial market for NRX-101, with no approved medicines for akathisia. This is a population the Company can readily address without a large commercial partner, given the relatively small number of psychiatrists who treat high-risk patients. The broad bipolar market constitutes 7 million people and an opportunity greater than $20 billion per year. With a best-in-class product profile, the Company projects NRX-101 sales in excess of $2 billion.
NRX-101 was awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression.
NRX-100 (IV ketamine) for Suicidal Depression
Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by FDA is electroconvulsive therapy (ECT).
According to the CDC, 3.5 million Americans make a plan for suicide each year.8 This represents a $3-5 billion market at expected pricing.
Based on the data in the trials referenced above, the Company's regulatory counsel has encouraged the Company to file an NDA for suicidal depression for NRX-100. This application has been in development and awaits 12-month stability data for filing, which is expected in 2024.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreements. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1 Nierenberg A, Lavin P, Javitt DC, et. al. NRX-101 vs lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior; a randomized prospective phase 2 trial. Int J Bipolar Dis 2023;11:28-38, STABIL-B
2 Nierenberg, et. al., A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior. Am Soc Clin Psych Annual Meeting 2024. ASCP Poster
3 Fava, M et. al., Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) Mol Psychiatry. 2020; 25(7): 1592–1603.
4 Grunebaum, et. al., Ketamine for Rapid Reduction of Suicidal Thoughts. Am J Psychiatry. 2018 Apr 1: 175(4): 327-335
5 Abbar, et. al. Ketamine for Acute Treatment of Severe Suicidal Ideation, BMJ 2022; 376
6 Anand, et. al, Ketamine is non-inferior to ECT for non-psychotic treatment resistant depression. NEJM 2023 388(25):2315-2325
7 Chow, C, et. Al., Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence
Pharmacotherapy 2020;40(6):565–574
8 CDC Suicide Data.
HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)
HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)
CisionCision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-to-proceed-with-two-new-drug-applications-in-2024-nrx-101-has-been-returned-to-the-company-for-filing-302185390.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing
New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 2024, based on two positive trials 1 2 and Breakthrough Therapy Designation. Potential revenue in 2025
NDA for NRX-100 (IV ketamine) in suicidal depression in advanced preparation for submission in 2024; based on four positive trials 3 4 5 6 and Fast Track Designation. Potential revenue in 2025
Gaining these approvals has the potential to yield more than $150 in revenue per NRXP share in the near term, at current share count
Planning for HOPE Therapeutics share distribution progresses; audit nearing completion – critical step towards a public listing
RADNOR, Pa., June 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that advice from regulatory counsel, which includes former senior officials from the Food and Drug Administration, supports filing two New Drug Applications (NDAs) in 2024: an application for Accelerated Approval for NRX-101 to treat bipolar depression in patients with akathisia and an application for approval of NRX-100 (IV ketamine) for treatment of suicidal depression.
(PRNewsfoto/NRx Pharmaceuticals)
(PRNewsfoto/NRx Pharmaceuticals)
While efficacy and safety data are now in hand, filing of the above applications is dependent upon completion of 12-month stability data in manufactured lots as required by FDA regulations.
As disclosed in an 8K filing, NRx will be filing the NRX-101 application without a commercial partner. The addressable market for the accelerated approval indication is such that a compact and efficient salesforce can be constructed by a small company, such as NRx, and current executives at NRx have previously held primary responsibility for launch of similar-sized pharmaceutical assets.
NRx continues work to enable the distribution of shares in Hope Therapeutics. This distribution is dependent upon completion of a public audit and successful review of an SEC Form 10.
"The NRx team has worked diligently since the end of the COVID pandemic to achieve these milestones for our shareholders and most importantly the patients we have always sought to help," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "Given the near-term market opportunity represented by an accelerated approval process, NRx anticipates a higher potential return to NRx investors associated with an NRx-led initiative than that which would likely be achieved with a large commercial partner."
NRX-101 for Bipolar Depression
NRX-101 is the Company's patented (Composition of Matter), oral combination of the NMDA antagonist D-cycloserine and lurasidone for bipolar depression. Data from two active control clinical trials vs. the standard of care, lurasidone, have shown comparable antidepressant efficacy with clinically important reductions in suicidality and/or akathisia. To the Company's knowledge, no other oral agent has demonstrated such a valuable profile.
Up to 15% of people treated with drugs in lurasidone's class develop akathisia7; this would constitute an estimated $3.7 billion initial market for NRX-101, with no approved medicines for akathisia. This is a population the Company can readily address without a large commercial partner, given the relatively small number of psychiatrists who treat high-risk patients. The broad bipolar market constitutes 7 million people and an opportunity greater than $20 billion per year. With a best-in-class product profile, the Company projects NRX-101 sales in excess of $2 billion.
NRX-101 was awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression.
NRX-100 (IV ketamine) for Suicidal Depression
Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by FDA is electroconvulsive therapy (ECT).
According to the CDC, 3.5 million Americans make a plan for suicide each year.8 This represents a $3-5 billion market at expected pricing.
Based on the data in the trials referenced above, the Company's regulatory counsel has encouraged the Company to file an NDA for suicidal depression for NRX-100. This application has been in development and awaits 12-month stability data for filing, which is expected in 2024.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreements. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1 Nierenberg A, Lavin P, Javitt DC, et. al. NRX-101 vs lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior; a randomized prospective phase 2 trial. Int J Bipolar Dis 2023;11:28-38, STABIL-B
2 Nierenberg, et. al., A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior. Am Soc Clin Psych Annual Meeting 2024. ASCP Poster
3 Fava, M et. al., Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) Mol Psychiatry. 2020; 25(7): 1592–1603.
4 Grunebaum, et. al., Ketamine for Rapid Reduction of Suicidal Thoughts. Am J Psychiatry. 2018 Apr 1: 175(4): 327-335
5 Abbar, et. al. Ketamine for Acute Treatment of Severe Suicidal Ideation, BMJ 2022; 376
6 Anand, et. al, Ketamine is non-inferior to ECT for non-psychotic treatment resistant depression. NEJM 2023 388(25):2315-2325
7 Chow, C, et. Al., Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence
Pharmacotherapy 2020;40(6):565–574
8 CDC Suicide Data.
HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)
HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)
CisionCision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-to-proceed-with-two-new-drug-applications-in-2024-nrx-101-has-been-returned-to-the-company-for-filing-302185390.html
SOURCE NRx Pharmaceuticals, Inc.
$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market
Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership
LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.
A Strategic Move in Response to Growing Demand
This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.
Quote from Mike Elliott, VP of Business Development
"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."
Expanding CyttaAIR's Reach
This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.
About Cytta Corp:
Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.
The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
About FIZUAS Unmanned Aircraft Systems
FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.
Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662
Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708
SOURCE: Cytta Corp.
https://finance.yahoo.com/news/cyttaair-partners-fizuas-dominate-american-120000070.html
Very good CYCA profile article recapping all the latest developments that are coming into play here. There is every reason for this company to gain significantly more market share in the increasingly important security and school safety field now.
From the article:
Technology Solutions Provider Addressing Various Industries for Integration, Streaming, Transfer and Storage of Video and Audio Data.
Partnered with FIZUAS Unmanned Aircraft Systems to Dominate the American Drone Reseller and Advanced Streaming Technology Market.
Launched Crisis Alert and Response Emergency System Mobile Application to Revolutionize School Safety.
Instant SOS Alert Automatically Triggers a Video Call That is Shared with All Emergency Responders Responsible for Protecting a School.
Initiative for Florida Law Enforcement Agencies Generates Overwhelming Response Amid New Drone Regulation Changes.
Strong Success for Groundbreaking AI-Enhanced Marketing Campaign in Florida.
Multiple Florida Police Departments and Sheriff's Offices Choosing CYCA CyttaCOMMS as their Drone Streaming Solution.
https://www.einpresswire.com/article/722643501/cytta-corp-and-fizuas-team-up-to-enhance-drone-and-streaming-tech-for-law-enforcement-cytta-corp-stock-symbol-cyca
$AVRW Seratopical skin care products are keeping the famous Nicole Kidman looking her best. Everyone can clearly see this.
When it comes to anti-aging skincare, Kidman's loyalty lies with Seralabs. Kidman, who has been working with the brand since 2020, told InStyle that she “loves using Seratopical because it makes my skin smooth and hydrated.” In honor of the brand ambassador’s birthday, Seralabs is offering 30 percent off sitewide all week with the code NK30.
Source:
https://www.instyle.com/nicole-kidman-birthday-favorite-beauty-products-8666305?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons
$AVRW Seratopical skin care products are keeping the famous Nicole Kidman looking her best.
When it comes to anti-aging skincare, Kidman's loyalty lies with Seralabs. Kidman, who has been working with the brand since 2020, told InStyle that she “loves using Seratopical because it makes my skin smooth and hydrated.” In honor of the brand ambassador’s birthday, Seralabs is offering 30 percent off sitewide all week with the code NK30.
Source:
https://www.instyle.com/nicole-kidman-birthday-favorite-beauty-products-8666305?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons
$SHOT News: Comedian and Actor Drew "Druski" Desbordes Joins Safety Shot as Their Newest Brand Ambassador
Druski Joins the Company's Impressive Portfolio of Creators and Celebrities to Boost Awareness of the Revolutionary Beverage with a Wide Range of Consumers
JUPITER, Fla., June 27, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) proudly announced today a partnership with American comedian and actor, Drew "Druski" Desbordes, as a brand ambassador.
Druski, most well known for his sketch-style comedy, entertains and embraces his 7.7 million followers on Instagram and 6.8 million on TikTok. He's collaborated with various musicians and appeared in music videos for artists including Jack Harlow, Drake, Lil Yachty, and more. Druski has done four nationwide tours in the U.S. and headlined his first comedy tour, "Coulda Woulda Shoulda", in March 2023. He's appeared in movies and television shows such as House Party and Grownish and is executive producing several TV & film productions for release in 2024. With a loyal fanbase and an aptitude for creating shareable content, Druski makes the perfect partner for Safety Shot.
Safety Shot is a first-of-its-kind functional beverage crafted with Essential B vitamins, antioxidants, electrolytes, and nootropics designed to rapidly rehydrate, and boost mental clarity, energy, and overall mood. Disrupting the industry and creating a category of one, Safety Shot is the world's first beverage to reduce blood alcohol content by supporting its metabolism in as little as 30 minutes. Druski's unique blend of authenticity and entertainment resonates strongly with his fan base, an attribute that the Company believes will translate well with their consumer. The Company aims to utilize the partnership with Druski to amplify brand awareness to a wider audience, leveraging his widespread appeal, vibrant energy, and creative content to enhance Safety Shot's visibility, drive virality, and build upon consumer interest and loyalty.
"We're so thrilled to welcome Druski as a Safety Shot brand ambassador," said Safety Shot Chief Revenue Officer Josh Wagner. "Druski's humor and relatable content have garnered him a massive following across social platforms. His ability to connect with a wide-ranging audience through his comedic talent and engaging personality makes him an ideal ambassador for Safety Shot. We're happy to welcome Druski to the team and we're excited for the partnership."
Other ambassadors to the brand include widely followed Youtube and social media personalities The Nelk Boys, Ryan Garcia, Matthew Espinosa, professional skateboarder Danny Way and more.
For more information, visit http://www.drinksafetyshot.com.
About Safety Shot, Inc
Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.
https://c212.net/c/img/favicon.png?sn=LA49778&sd=2024-06-27 View original content to download multimedia:https://www.prnewswire.com/news-releases/comedian-and-actor-drew-druski-desbordes-joins-safety-shot-as-their-newest-brand-ambassador-302183923.html
SOURCE Safety Shot